Developing gene therapies involving gene editing is a rapidly evolving field with large potential implications for improving health for both rare and common diseases. Ensuring that these technologies are developed safely, efficiently, and fairly is essential. To better understand the ethical considerations and regulatory requirements and challenges with gene therapies involving gene editing that may advance precision health. Through a multistakeholder workshop and subsequent engagements, multiple ethical and regulatory barriers to developing and implementing gene therapies involving gene editing were identified. Eight major themes emerged that warrant careful consideration, including (1) objectives (treatment, risk reduction, and enhancement) for the intervention; (2) competing interests of safety, equity, and desire for research efficiencies; (3) unique aspects of gene editing related to rare and ultrarare genetic conditions; (4) considerations in the pediatric population; (5) regulatory requirements and ethics oversight; (6) challenges with long-term follow-up and data sharing; and (7) communication. To promote the safe, efficient development of gene therapies involving gene editing that will reach their full potential, all stakeholders will have to undertake an unprecedented degree of collaboration. However, this will be essential to ensure that these interventions are effective, ethically sound, and patient-centered.
ConsortiumIHGS. Finishing the euchromatic sequence of the human genome. Nature, 2004; 431(7011):931–945.
2.
DzauVJ, GinsburgGS. Realizing the full potential of precision medicine in health and health care. JAMA, 2016; 316(16):1659–1660.
3.
RobertsMC, HoltKE, Del FiolG, et al.Precision public health in the era of genomics and big data. Nat Med, 2024; 30(7):1865–1873.
4.
WirthT, ParkerN, Ylä-HerttualaS. History of gene therapy. Gene, 2013; 525(2):162–169.
5.
LiH, YangY, HongW, et al.Applications of genome editing technology in the targeted therapy of human diseases: Mechanisms, advances and prospects. Signal Transduct Target Ther, 2020; 5(1):1.
FrangoulH, AltshulerD, CappelliniMD, et al.CRISPR-Cas9 gene editing for sickle cell disease and β-Thalassemia. N Engl J Med, 2021; 384(3):252–260.
8.
KanterJ, WaltersMC, KrishnamurtiL, et al.Biologic and clinical efficacy of LentiGlobin for sickle cell disease. N Engl J Med, 2022; 386(7):617–628.
9.
JinekM, ChylinskiK, FonfaraI, et al.A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science, 2012; 337(6096):816–821.
10.
KhanSH. Genome-editing technologies: Concept, pros, and cons of various genome-editing techniques and bioethical concerns for clinical application. Mol Ther Nucleic Acids, 2019; 16:326–334.
11.
YinH, KauffmanKJ, AndersonDG. Delivery technologies for genome editing. Nat Rev Drug Discov, 2017; 16(6):387–399.
12.
DoudnaJA. The promise and challenge of therapeutic genome editing. Nature, 2020; 578(7794):229–236.
13.
HuntJMT, SamsonCA, RandAD, et al.Unintended CRISPR-Cas9 editing outcomes: A review of the detection and prevalence of structural variants generated by gene-editing in human cells. Hum Genet, 2023; 142(6):705–720.
14.
ChmpE. Guideline on Follow-Up of Patients Administered with Gene Therapy Medicinal Products. European Medicines Agency (EMA): London; 2009.
15.
AyC, ReinischA. Gene therapy: Principles, challenges and use in clinical practice. Wien Klin Wochenschr, 2025; 137(9–10):261–271.
16.
HouseC. Chatham house rule. 2017.
17.
WaltzM, JuengstET, EdwardsT, et al.The view from the benches: Scientists’ perspectives on the uses and governance of human gene-editing research. Crispr J, 2021; 4(4):609–615.
18.
GillmoreJD, GaneE, TaubelJ, et al.CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med, 2021; 385(6):493–502.
19.
NarodSA. BRCA mutations in the management of breast cancer: The state of the art. Nat Rev Clin Oncol, 2010; 7(12):702–707.
20.
KarnV, SandhyaS, HsuW, et al.CRISPR/Cas9 system in breast cancer therapy: Advancement, limitations and future scope. Cancer Cell Int, 2022; 22(1):234.
21.
GrundySM, StoneNJ, BaileyAL, et al.2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019; 139(25):e1082–e1143.
22.
LewisBS. First-in-human trial of PCSK9 gene editing therapy for lowering cholesterol: A new frontier in cardiovascular pharmacotherapy? News from AHA. Eur Heart J Cardiovasc Pharmacother, 2024; 10(2):87–88.
23.
WaltzM, WalkerRL, FlattMA, et al.Challenging the boundaries between treatment, prevention, and enhancement in human genome editing. Crispr J, 2024; 7(4):180–187.
24.
HiranoA, HsuP-K, ZhangL, et al.DEC2 modulates orexin expression and regulates sleep. Proc Natl Acad Sci USA, 2018; 115(13):3434–3439.
25.
RichterW, MennitiFS, ZhangH-T, et al.PDE4 as a target for cognition enhancement. Expert Opin Ther Targets, 2013; 17(9):1011–1027.
26.
KaldsP, CrispoM, LiC, et al.Generation of double-muscled sheep and goats by CRISPR/Cas9-Mediated knockout of the myostatin gene. Methods Mol Biol, 2022; 2495:295–323.
27.
TuftsC. Causes of clinical failures vary widely by therapeutic class, phase of study. Tufts CSDD Study Assessed Compounds Entering Clinical Testing in, 2000; 9:1–4.
28.
WilsonJM. Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol Genet Metab, 2009; 96(4):151–157.
DunbarCE, HighKA, JoungJK, et al.Gene therapy comes of age. Science, 2018; 359(6372):eaan4672.
31.
CollinsFS, GottliebS. The next phase of human gene-therapy oversight. N Engl J Med, 2018; 379(15):1393–1395.
32.
HaendelM, VasilevskyN, UnniD, et al.How many rare diseases are there? Nat Rev Drug Discov, 2020; 19(2):77–78.
33.
ShoreCK, WorkuTL, KahnJ. Rare disease innovation at the FDA—opportunities for implementation. JAMA, 2024; 332(23):1973–1974.
34.
MeaseC, FermaglichLJ, JacklerK, et al.Determining commonalities in the experiences of patients with rare diseases: A qualitative analysis of us food and drug administration patient engagement sessions. Patient, 2024; 17(1):25–37.
35.
LidzCW, AppelbaumPS, GrissoT, et al.Therapeutic misconception and the appreciation of risks in clinical trials. Soc Sci Med, 2004; 58(9):1689–1697.
36.
PentzRD, WhiteM, HarveyRD, et al.Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials. Cancer, 2012; 118(18):4571–4578.
37.
DowlingJJ, PirovolakisT, DevakandanK, et al.AAV gene therapy for hereditary spastic paraplegia type 50: A phase 1 trial in a single patient. Nat Med, 2024; 30(7):1882–1887.
38.
KimJ, HuC, Moufawad El AchkarC, et al.Patient-customized oligonucleotide therapy for a rare genetic disease. N Engl J Med, 2019; 381(17):1644–1652.
39.
GleesonJG, BennettCF, CarrollJB, et al.Personalized antisense oligonucleotides ‘for free, for life’ — the n-Lorem foundation. Nat Med, 2023; 29(6):1302–1303.
40.
GelinasL, LynchHF, BiererBE, et al.When clinical trials compete: Prioritising study recruitment. J Med Ethics, 2017; 43(12):803–809.
41.
LowensteinPR. Clinical trials in gene therapy: Ethics of informed consent and the future of experimental medicine. Curr Opin Mol Ther, 2008; 10(5):428–430.
AiutiA, PasinelliF, NaldiniL. Ensuring a future for gene therapy for rare diseases. Nat Med, 2022; 28(10):1985–1988.
44.
KliegmanM, ZaghlulaM, AbrahamsonS, et al.A roadmap for affordable genetic medicines. Nature, 2024; 634(8033):307–314.
45.
FoxT, BuerenJ, CandottiF, et al.; AGORA Initiative. Access to gene therapy for rare diseases when commercialization is not fit for purpose. Nat Med, 2023; 29(3):518–519.
46.
ArcidiaconoJ. International harmonization for cell and gene therapy products. Regulatory Aspects of Gene Therapy and Cell Therapy Products: A Global Perspective. Springer; 2023. pp. 235–240.
47.
BamfordK, WoodS, ShawR. Standards for gene therapy clinical trials based on pro-active risk assessment in a London NHS Teaching Hospital Trust. QJM, 2005; 98(2):75–86.
48.
BrooksPJ, OttingerEA, PorteroD, et al.The platform vector gene therapies project: Increasing the efficiency of adeno-associated virus gene therapy clinical trial startup. Hum Gene Ther, 2020; 31(19–20):1034–1042.
49.
GoyalS, TisdaleJ, SchmidtM, et al.Acute myeloid leukemia case after gene therapy for sickle cell disease. N Engl J Med, 2022; 386(2):138–147.
50.
KonkleBA, CoffinD, PierceGF, et al.; Members of the WFH Gene Therapy Registery Steering Committee. World federation of hemophilia gene therapy registry. Haemophilia, 2020; 26(4):563–564.
51.
LinZ, OwenAB, AltmanRB. Genomic research and human subject privacy. Science, 2004; 305(5681):183.
52.
BonomiL, HuangY, Ohno-MachadoL. Privacy challenges and research opportunities for genomic data sharing. Nat Genet, 2020; 52(7):646–654.
53.
Lekstrom-HimesJ, AugustineEF, BrowerA, et al.Data sharing to advance gene-targeted therapies in rare diseases. Am J Med Genet C Semin Med Genet, 2023; 193(1):87–98.
